Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 15-95 

High dose EC x 3 supported by PBSC vs. EC/AC x 4 followed by CMF as adjuvant treatment for high risk operable stage II and stage III breast cancer in premenopausal and young postmenopausal (less than 65 years) patients

DESIGN

Design Trial 15-95

Results & Publications


Presentations


Publications

Study Chairs
Dr. Russel Basser - Melbourne, Australia
Prof. Monica Castiglione - Bern, Switzerland

Statistician
Dr. Zhuoxin Sun

Lead Trial Coordinator
Holly Shaw

Director of Data Management
Lynette Blacher

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990

Email: ibcsg10-15@fstrf.org

Date of Activation
July 1995

Date of Closure
March 15, 2000

Targeted Accrual
300 patients

Final Accrual
344 patients


Results Publications Results & Publications
Other Pathology


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print